Are the Needs of Research Reflected in Copyright Decision-Making? An analysis of Copyright Councils & Consultations – Part II – Go Health Pro

Are the Needs of Research Reflected in Copyright Decision-Making? An analysis of Copyright Councils & Consultations – Part II – Go Health Pro

Image by Peter Mello via Flickr In the first part of this blog, we explored the structure of formalised copyright councils, finding that efforts to ensure balance between the interests of rightsholders and users were the exception not the rule. Furthermore, it was only in a small minority of cases that the representation of research … Read more

Zacks Small Cap Research – TELO Announces Breakthrough – Go Health Pro

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

Are the Needs of Research Reflected in Copyright Decision-Making? An analysis of Copyright Councils & Consultations – Part I – Go Health Pro

Are the Needs of Research Reflected in Copyright Decision-Making? An analysis of Copyright Councils & Consultations – Part II – Go Health Pro

Image by Peter Mello via Flickr The interests of research are not necessarily heard or represented when decisions are being made about copyright laws that affect them. Both permanent and temporary consultation structures more often than not fail to ensure that there is a channel open for this. Part one of this two-part blog introduces … Read more

Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro

Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketing shift from BioLine’s internal team to Ayrmid’s subsidiary Gamida Cell. Gamida cell is commercializing Omisirge, a cell therapy for treating blood cancers in patients who need a stem cell transplant. … Read more

Zacks Small Cap Research – SDOT: Sadot Group Announces Appointment of new CEO – Go Health Pro

By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT New CEO On February 13, 2025, Sadot Group (NASDAQ:SDOT) announced the appointment of Catia Jorge as new Chief Executive Officer. Ms. Jorge has nearly 30 years of experience in agricultural markets, commodity trading, and operational leadership. Most recently, she served as Brazil Country Head … Read more

x